Pharvaris PHVS 深 沪
等待开盘 09-24 09:30:00 美东时间
33.07
-2.130
-6.05%
华盛通- 最 高35.3082
- 今 开35.19
- 成交量 65.43万股
- 最 低 32.87
- 昨 收 35.20
- 总市值 23.22亿
- 52周最高 43.25
- 市盈率 静 --
- 换手率 0.93%
- 52周最低 20.65
- 委 比 42.86%
- 总股本 7020.45万
- 历史最高 43.25
- 量 比 0.86
- 振 幅 6.93%
- 历史最低 1.77
- 每 手 1
- 风险率 4.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG slashed the price target for Canaan Inc – ADR (NASDAQ:CAN) from $3 to $2. BTIG analyst Gregory Lewis main...
09-09 21:04
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Why Is Pharvaris Stock Soaring Tuesday?
On Tuesday, Pharvaris NV (NASDAQ:PHVS) reported positive topline results from its late-stage clinical trial evaluating the oral drug deucrictibant extended-release (XR) for preventing hereditary angioedema (HAE) attacks. Following the announcement, the stock jumped over 17%. The trial met all primar...
09-08 21:59
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
The latest update is out from Pharvaris ( ($PHVS) ). Pharvaris N.V., based in L...
09-08 21:28
Wedbush Reiterates Outperform on Pharvaris, Maintains $42 Price Target
Wedbush analyst Laura Chico reiterates Pharvaris (NASDAQ:PHVS) with a Outperform and maintains $42 price target.
09-08 21:20
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Pharvaris announced statistically significant results from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prevention, showing an 83% reduction in attack rate vs. placebo. The study met all primary and secondary endpoints, with deucrictibant XR well-tolerated and effective across all HAE types. The company plans to submit marketing applications in early 2027 and host a conference call to discuss the data.
09-08 10:50
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
Pharvaris summarized findings from the Bradykinin Symposium 2026, highlighting advancements in bradykinin B2 receptor antagonist research, particularly deucrictibant, for treating bradykinin-mediated angioedema. Studies demonstrated deucrictibant's efficacy in reducing attack severity and improving patient outcomes, with favorable safety profiles across prophylactic and on-demand settings. Preclinical models validated its receptor interactions, a...
09-03 10:50
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
